If you are wondering whether Bristol-Myers Squibb is priced attractively right now, you are not alone. This article walks ...

Bristol-Myers Squibb (BMY) has been drawing attention after its shares closed at $56.72, leaving investors weighing how ...

Cash management is critical for pharmaceutical companies: The ability to fund drug innovation can make the difference between ...

A federal appeals court on Wednesday blocked a Trump administration plan to require hospitals serving low-income Americans to ...

Poplar Therapeutics Inc. launched on Wednesday capitalized with $50 million Series A financing and led by Chip Baird, the ...

Fintel reports that on January 7, 2026, UBS upgraded their outlook for Bristol-Myers Squibb (NYSE:BMY) from Neutral to Buy.

The big news in the drug sector is the emergence of GLP-1 weight loss drugs, but dig deeper, and you'll find relatively cheap ...

Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ...

Bristol Myers Squibb (BMY) is undervalued and poised for growth, with strong dividends and robust financials. Read here for ...

Deep-pocketed investors have adopted a bullish approach towards Bristol-Myers Squibb (NYSE:BMY), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

Bristol Myers Squibb has a robust pipeline with plenty of active programs, and its outlook for the next decade remains strong ...

Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Study Overview Bristol-Myers Squibb ...